Resistance to lamivudine therapy: Is there more than meets the eye?

Gut

Volumn 54, Issue 1, 2005, Pages 9-10

  Dusheiko, G ^a   Bertoletti, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; LAMIVUDINE;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CYTOTOXIC T LYMPHOCYTE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; NOTE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; VIREMIA;

CD8-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 10844290327     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.047548     Document Type: Note

References (22)

1. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-80.
2. Haaziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
3. Dusheiko GM. Interferon alpha: Biology, pharmacology and therapy for chronic viral hepatitis. In: Thomson AW, Lotze MT, eds. The cytokine handbook. London: Elsevier Science, 2003:1233-54.
4. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-Summary of a workshop. Gastroenterology 2001;120:1828-53.
5. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106.
6. Perrillo RP. How will we use the new antiviral agents for hepatitis B? Curr Gastroenterol Rep 2002;4:63-71.
7. Dusheiko G. A pill a day, or two, for hepatitis B? Lancet 1999;353:1032-3.
8. Kim JW, Lee HS, Woo GH, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001;33:403-5.
9. Wiegend J, Tischendorf JJ, Nashan B, et al. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Z Gastroenterol 2004;42:15-18.
10. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
11. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55.
12. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-73.
13. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-32.
14. Ling R, Mutimer D, Ahmed N, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-13.
15. Zollner B, Petersen J, Schafer P, et al. Subtype-dependent response of hepatitis B virus during the early phase or lamivudine treatment. Clin Infect Dis 2002;34:1273-7.
16. Zollner B, Petersen J, Puchhammer-Stockl E, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004;39:42-50.
17. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968-75.
18. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 2001;33:963-71.
19. Lin C-L, Tsai S-L, Lee TH, et al. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 2005;54:152-61.
20. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-58.
21. Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707-19.
22. Kakimi K, Isogowa M, Chung J, et al. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy or persistent viral infections. J Virol 2002;76:8609-20.